Quality of Life
Outcomes achieved using a digital service model for COPD
Despite their progressive condition, service users returned reassuringly stable serial quality of life scores.
Let's look at what that means when considering how Lenus can transform the traditional COPD pathway.
How the Lenus Service has demonstrated stable quality of life for users
Average EQ-5D score increase from baseline over 600 days
Average EQ-5D score increase over each 100 day period
More information on the data visualised
Variable with participant completion of EQ-5D entries and time period.
Max 225 (at baseline).
|Inclusion Criteria||RECEIVER and Dynamic-Scot 1 participants.|
EQ-5D Visual analogue scale score.
Service users self-access their health on a vertical visual scale ranging from 0, "worst imaginable health", to 100, "best imaginable health".
Data for each service user was censored at whichever time period was shortest:
- EQ-VAS: The EQ-5D5L Visual analogue scale was used to record self-rated health on a vertical visual scale ranging from 0 (worst imaginable health) to 100 (best imaginable health).
- Users had the opportunity to complete an EQ-VAS entry once every 28 days.
- The mean score reported over each 100-day time window is shown.
ClinicalTrials.gov Identifier: NCT04240353
The feasibility and service adoption observational cohort RECEIVER trial was commenced in September 2019 by NHS Greater Glasgow and Clyde to evaluate the implementation and efficacy of the Lenus COPD Service with high-risk COPD participants matched 1:5 to a control cohort using de-identified contemporary routine clinical data. In March 2021, 'RECEIVER' recruitment was paused and a 'Dynamic-Scot' cohort was established through remote recruitment in the Covid-19 service scale-up to routine care. The protocol is published here with the full results available here.
|Control||RECEIVER||Dynamic-Scot 1||Service users|
Selected from the NHS Greater Glasgow and Clyde SafeHaven dataset.
Diagnosis of COPD + a COPD-related hospital admission within a 14-day window of a reference RECEIVER trial participant's onboarding date were criteria for entry.
From these criteria, the optimal ~5 matches for each RECEIVER participant were determined based on sex and age whilst excluding duplicate control patients or individuals subsequently onboarded to Lenus COPD.
|At least one severe COPD exacerbation in the year prior to onboarding to Lenus COPD and/or chronic hypercapnic respiratory failure/sleep disordered breathing requiring NIV/CPAP treatment.||Onboarded at least 365 days before 31/08/2021 (the data censor date for analyses).||RECEIVER and Dynamic-Scot 1 participants.|
|1st Participant Index Date||3rd September 2019||3rd September 2019||15th May 2020||3rd September 2019|
|Censor Date||31st August 2021|
Medtech Innovation Briefing
The National Institute of Health and Care Excellence (NICE) has developed a medtech innovation briefing (MIB) on Lenus COPD Support Service for remotely managing chronic obstructive pulmonary disease available here.
Get in touch
Got a service in mind for Lenus? Talk to us today.